Information Provided By: 
Fly News Breaks for October 4, 2019
BHVN
Oct 4, 2019 | 07:48 EDT
Canaccord analyst Sumant Kulkarni noted Biohaven Pharmaceutical provided an update on the NDA for Rimegepant to be used in the treatment of migraines. The update suggested no major safety issues and said its priority review with an action date in Q1 remains on track. The analyst said a potential series of events in Q4 could create a nice setup for the shares. Kulkarni reiterated his Buy rating and $80 price target on Biohaven Pharmaceuticals shares.
News For BHVN From the Last 2 Days
BHVN
Apr 23, 2024 | 09:00 EDT
UBS raised the firm's price target on Biohaven to $60 from $59 and keeps a Buy rating on the shares after hosting meetings with management. The stock's 28% selloff since April 15 represents an "attractive opportunity," the analyst tells investors in a research note. The firm sees an attractive risk/reward into the Phase 1 degrader data on May 29. A key opinion leader viewed Biohaven's degrader platform as an elegant approach to various disease modalities, says UBS. The firm says the stock's bear case is overdone.
